Tony Berberabe, MPH

Articles

Real-World OS Outcomes Are Similar for Frontline CDK4/6 Inhibitor Combos in HR+, HER2– Breast Cancer

December 12th 2024

Retrospective data showed there was no OS difference between 3 frontline CDK4/6 inhibitor combos in HR-positive breast cancer.

SHR-A1811 Shows Initial Antitumor Activity, Tolerability in HER2+ Breast Cancer

December 11th 2024

SHR-A1811 monotherapy demonstrated high clinical activity and was well tolerated in patients with HER2-positive breast cancer.

Pirtobrutinib Improves PFS in Previously Treated CLL/SLL

December 10th 2024

Pirtobrutinib improved progression-free survival in previously treated chronic lymphocytic leukemia and small lymphocytic lymphoma.

Cilta-Cel Prolongs OS in Lenalidomide-Refractory Multiple Myeloma

October 1st 2024

Cilta-cel reduced the risk of death by 45% compared with standard of care in patients with multiple myeloma, according to the CARTITUDE-4 study.

Radium-223 Before Docetaxel Demonstrates Better QOL in mCRPC, With No Difference in Survival

September 27th 2024

Radium-223 prior to docetaxel improved quality of life and tolerability in patients with metastatic castration-resistant prostate cancer according to data from the RAPSON trial.

Dato-DXd Demonstrates Efficacy, Safety in Platinum-Resistant Ovarian and Endometrial Cancers

September 18th 2024

Datopotamab deruxtecan shows antitumor activity in patients with advanced/metastatic ovarian and endometrial cancer and progressive disease following platinum chemotherapy.

Darolutamide Plus ADT Improves rPFS in mHSPC

September 16th 2024

Darolutamide plus ADT shows PFS benefit without docetaxel in metastatic hormone-sensitive prostate cancer.

Histologic Distinctions and Optimized Imaging Carve New Paths for Individualized PTCL Management

September 7th 2024

Neha Mehta-Shah, MD, MSCI, discusses unmet needs and future developments in the treatment of patients with peripheral T-cell lymphoma.

Improved OS, Cost Effectiveness Are Necessary to Shift Later-Line TKIs to Frontline CML-CP

September 6th 2024

Elias Jabbour, MD, discusses the potential activity and financial benefit of novel and emerging TKIs for first-line management of chronic phase CML.

Immunotherapy Could Represent New Treatment Avenue in T-Cell Lymphoma

September 5th 2024

The investigation of treatments harnessing the immune system in patients with T-cell lymphoma could lead to "a new era" of therapy for this patient population.

CAR T-Cell Therapy Is Safe, Feasible in Outpatient Setting for NHL

June 14th 2024

The administration of CAR T-cell therapy in the outpatient setting was deemed feasible and safe in patients with relapsed/refractory NHL.

CAN-2409 Plus Valacyclovir Shows Favorable Tolerability, Induces Immune Responses in NSCLC

June 4th 2024

In patients with NSCLC refractory to anti-PD(L)1 therapy, CAN-2409 (adenovirus) plus valacyclovir co-administered with ICI therapy showed acceptable tolerability and potential for immune modulation

Extended Lymphadenectomy Shows No DFS, OS Benefit During Radical Cystectomy in Urothelial Cancer

May 3rd 2024

Concurrent radical cystectomy and extended lymph node dissection did not show benefit vs standard lymph node dissection in muscle invasive urothelial cancer.

Tislelizumab Plus Chemo Generates Responses in Locally Advanced Cervical Cancer

March 16th 2024

Neoadjuvant tislelizumab in combination with chemotherapy was safe and produced responses in patients with locally advanced cervical cancer.

Presence of ctDNA Does Not Predict Benefit of Adjuvant Chemotherapy in Stage II Colon Cancer

January 22nd 2024

Adjuvant chemotherapy did not improve circulating tumor DNA clearance in patients with stage II colon cancer with baseline circulating tumor DNA.

MRD Positivity Correlates With Allogeneic Transplant Benefits in NPM1-Mutated AML

December 10th 2023

The presence of molecular minimal residual disease following induction chemotherapy can be used to determine patients with NPM1-mutated acute myeloid leukemia who may benefit from allogeneic transplant in first remission, including those with FLT3 ITD–mutated disease.

Epcoritamab Monotherapy Demonstrates High Response Rates in High-Risk Relapsed/Refractory CLL

October 9th 2023

Treatment with subcutaneous epcoritamab-bysp elicited rapid and durable responses, including an encouraging complete response rate, and manageable safety in high-risk patients with relapsed/refractory chronic lymphocytic leukemia.

Forimtamig Delivers Responses in Relapsed/Refractory Multiple Myeloma

September 29th 2023

Forimtamig monotherapy generated high overall response rates and durable responses in all subgroups of patients with relapsed/refractory multiple myeloma enrolled in a phase 1a dose-escalation trial.

Improved Molecular Understanding of AP/BP MPN Better Informs Management Approaches

September 8th 2023

Developing an optimal treatment strategy for patients with accelerated- or blast-phase myeloproliferative neoplasms requires consideration of a patient's ability to tolerate intensive induction therapy, their eligibility for allogeneic stem cell transplant.

Ongoing Investigations of Nelabarine and Daratumumab May Improve Outcomes in T-ALL

September 8th 2023

Investigating the addition of novel agents to cytotoxic chemotherapy may help prevent relapse in patients with T-cell acute lymphoblastic leukemia by bolstering the efficacy of these standard frontline therapies.